HOUSE-WELLNESS-FOODS
3.5.2016 13:51:54 CEST | Business Wire | Press release
A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, reversing disease trends and increasing reproduction. The study, published in the International Journal of Scientific and Research Publications , Volume 6, Issue 3, March 2016, is welcome news for the East Asian fishing industry, which has been plagued by vibriosis, linked to the presence of Vibrio parahaemolyticus and other bacteria found in salt water. Feed LP20® is proven safe, and represents groundbreaking evidence of the effectiveness of heat-treated lactobacillus, as measured in conjunction with this crucial species.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160503005537/en/
Feed LP20® was developed for livestock and fisheries as an alternative to antibiotic regimens, and as a functional product for improving immune function and productivity. It contains 20% heat-killed Lactobacillus plantarum L-137 (HK L-137) . Heat treatment of HK L-137, the central ingredient of House Wellness Foods’ Feed LP20® and Immuno-LP20® , is key to those products’ effectiveness, making them stable long-term at varying temperatures, easily handled, even under pressure, and maintaining immunostimulant properties while resisting degradation by water and gastric acids.
HWF is regarded as a pioneer in the continuous study of HK L-137, and Immuno-LP20 has been hugely successful as an immunobiotic, enjoying prominence among health-conscious consumers in the U.S. and worldwide as a natural aid to the body’s innate ability to defend itself against seasonal illness and allergy.
A joint study conducted in cooperation with Vietnam’s Can Tho University proved conclusively that the addition of as little as 100 ppm of Feed LP20 boosts immune function in the shrimp population and improves survival and growth rates, which were significantly (P<0.05) higher compared to other feeds. Immune parameters consisted of total haemocyte count, differential haemocyte count, phenoloxidase activity, phagocytic activity and clearance efficiency. The study also showed a critical synergistic effect in conjunction with B-glucan, an activator of immune system functions in aquaculture.
House Wellness Foods is pursuing sales and promotion of Feed LP20 for livestock and aquaculture in support of these industries and in the hope of ameliorating the blight of worldwide hunger.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160503005537/en/
Contact:
House Wellness Foods
Onoda Satoru, +81-3-5211-7220
Onoda_Satoru@house-wf.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
